LYEL FY2023 SEC EDGAR DEF 14A

Lyell Immunopharma, Inc. CEO pay ratio

The CEO earned $473K in FY2023 against median worker pay of $236,291 · Chemicals & Pharmaceuticals.

State
DE
Filing date
2024-04-22
Industry
Chemicals & Pharmaceuticals
Fiscal year
FY2023

Data updated August 2026

Subscribe to Lyell Immunopharma, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
2:1
Below Average (Scale: 0–1000:1)
CEO pay
$473K
Median worker
$236,291

Latest filing FY2023. This company's newest DEF 14A on file is for FY2023, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.

Answer first

Lyell Immunopharma, Inc. reported a 2:1 CEO-to-worker pay ratio in FY2023 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.

Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Pay ratio
2:1
FY2023 disclosed
CEO total
$473K
Summary Compensation Table total
Median worker
$236,291
Dodd-Frank median employee

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2023

A component-level pay breakdown is not reported in Lyell Immunopharma, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
2:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$473K
Companies in Industry
168
vs. Industry Median
Below

Lyell Immunopharma, Inc.: near-parity Item 402(u) ratio

Lyell Immunopharma, Inc. stamps FLOOR · ELITE-MED at 2:1 against $236,291 median worker pay in FY2023. the CEO earned 2× the median employee ($236,291) in FY2023.

At $236,291 median worker pay, the FLOOR stamp is near pay-parity territory under MICRO CEO total.

CEO Total Pay

$473K

FY2023 Summary Compensation, below median

Pay Ratio

2:1

Below typical

What FY2023 shows for Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. stamps FLOOR · ELITE-MED at 2:1 against $236,291 median worker pay in FY2023. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Lyell Immunopharma, Inc.'s $473K CEO total is at or below the $7.9M industry median CEO pay.

Lyell Immunopharma, Inc. stamps FLOOR · MICRO · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2023

Total Compensation
$473K
Median Employee Pay
$236,291
Pay Ratio
2:1
Filing Date
2024-04-22

Company Info

Ticker
LYEL
CIK
1806952
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
SEC EDGAR DEF 14A for CIK 1806952, FY2023. Informational only, not investment advice. Verify on EDGAR.

Read with Lyell Immunopharma, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MICRO · ELITE-MED.

Data sourced from SEC EDGAR DEF 14A for Lyell Immunopharma, Inc. (CIK 1806952), FY2023. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.